$Cassava Sciences (SAVA.US)$ Very Bullish 🚀An Open Letter ...
$Cassava Sciences (SAVA.US)$ Very Bullish 🚀An Open Letter from Executive Chairman Rick Barry to the Cassava Community:
Shareholders, Employees, Principal Investigators, Patients and their Loved Ones
´ Our ultimate goal is to develop an effective treatment for a patient population that has little hope and few therapeutic options.
Our first Phase 3 trial is expected to read out by December 2024, with 804 patients randomized 1:1 between simufilam and placebo. The second Phase 3 trial of 1,125 patients (randomized 1:1:1 between two dose levels of simufilam and placebo) is expected to conclude by June 2025. If these trials are successful, Cassava can change the world.’
Shareholders, Employees, Principal Investigators, Patients and their Loved Ones
´ Our ultimate goal is to develop an effective treatment for a patient population that has little hope and few therapeutic options.
Our first Phase 3 trial is expected to read out by December 2024, with 804 patients randomized 1:1 between simufilam and placebo. The second Phase 3 trial of 1,125 patients (randomized 1:1:1 between two dose levels of simufilam and placebo) is expected to conclude by June 2025. If these trials are successful, Cassava can change the world.’
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
